DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for papillary thyroid carcinoma — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePapillary thyroid carcinoma maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for papillary thyroid carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) — PRKAR1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pcgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KJZ · 1.347 Å · ligand CYCLIC GUANOSINE MONOPHOSPHATE (PCG). Experimental structure, not a prediction.
What the evidence adds up to
A 2020 study reports that papillary thyroid carcinoma accounts for more than 80% of all thyroid cancer cases. In low-risk patients with tumours 4 cm or smaller, a single size threshold of 4 cm was found to maximise prognostic discrimination; tumours larger than 4 cm carried a five times higher risk of recurrence than those 4 cm or smaller. The study’s purpose was to determine an effective treatment strategy for small unilateral papillary thyroid carcinoma in this low-risk group, but no specific outcome data or survival figures are given in the abstract.
A 2016 review describes the molecular genetic mechanisms of papillary thyroid carcinoma formation, focusing on the role of ionising radiation, tumour microenvironment, inflammation, and the nuclear transcription factor NF-κB in cancer initiation and development. No clinical outcomes or patient numbers are provided.
A 2022 single-institution study examined reoperation for locoregional recurrence in patients with radioactive iodine-refractory papillary thyroid carcinoma. The abstract states that repetitive surgery is one form of local therapy for recurrent or metastatic disease but is hampered by technical challenges and complications. The study aimed to evaluate the efficacy of reoperations and their effect on disease progression, but no concrete results, response rates, or survival data are reported in the abstract.
What is still missing are prospective randomised trials comparing reoperation to other salvage therapies for radioactive iodine-refractory disease, clear stratification of low-risk patients who might safely avoid completion thyroidectomy, and funding for studies that translate the molecular mechanisms (NF-κB, inflammation) into actionable therapeutic targets.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Financial Times Prentice Hall eBooks · 2004 · 17 citations
The International Business Environment
AbstractPapillary thyroid microcarcinoma, NI-EFV, when stringently selected for, lacks metastasis at presentation and follows an extremely indolent clinical course, even when treated conservatively without RAI therapy. Provided stringent inclusion criteria are met, classification of subcentimeter mPTC, NI-EFV as NIFTP should be considered in order to avoid overtreatment of these biologically indolent lesions.
Thirty years after the Chernobyl accident: Molecular genetic mechanisms of carcinogenesis of the thyroid gland
AbstractThe review presents data on the basic molecular genetic mechanisms of formation of papillary thyroid carcinoma. The participation of ionizing radiation in the cancer pathogenesis was analyzed. The role of tumor microenvironment, inflammation, and nuclear transcription factor NF-κB in the initiation and development of papillary thyroid carcinoma was shown.
Annals of Cancer Research and Therapy · 2022 · 1 citations · open access
Outcomes of reoperation for locoregional recurrence in radioactive-iodine refractory papillary thyroid carcinoma patients: a single-institution experience
AbstractBackground: For recurrent or metastatic radioactive iodine-refractory (RAI-R) papillary thyroid carcinoma (PTC), repetitive surgery is one form of local therapy that is evolving but hampered by technical challenges and complications. The goals of this study were to evaluate the efficacy of reoperations for local relapses of RAI-R PTC and to determine the effect of surgical treatment on disease progression.
International Journal of Innovative Science and Research Technology (IJISRT) · 2020 · 0 citations · open access
Hemithyroidectomy: Papillary Thyroid Carcinoma in Low Risk Group Patients
AbstractPapillary thyroid cancer (PTC) is the most prevalent histologic subtype of thyroid cancer accounting for more than 80% of all cases. A single size threshold of 4 cm maximized prognostic discrimination with tumors >4 cm associated with a five times higher risk of recurrence than those ≤4 cm. The purpose of this present study was to determine an effective treatment strategy for patients with small unilateral papillary thyroid carcinoma in a low risk group below tumor size ≤ 4 cm.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
